Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings

ObjectivesWe developed a conceptual model to define key concepts associated with patients’ experiences with the signs, symptoms, and impacts of non-metastatic castration-resistant prostate cancer (M0-CRPC).MethodsA targeted review of peer-reviewed literature, and other publicly available information, identified and categorized symptoms and impacts related to early-stage prostate cancer. Semi-structured interviews with five clinical experts helped determine the most relevant and important concepts for patients with M0-CRPC. Qualitative interviews with 17 patients with M0-CRPC identified the most frequently experienced symptoms and impacts, and their degree of interference with patients’ lives. The findings from these three lines of evidence were summarized in a conceptual model.ResultsLiterature searches identified mainly urinary, intestinal, and sexual symptoms. Experts noted the symptoms most frequently mentioned by patients include erectile dysfunction, loss of sexual desire or interest, incontinence/leaking, urgency, and hot flashes. Patient interviews confirmed the high frequency of erectile dysfunction, loss of libido, urinary urgency, and incontinence. The most frequently mentioned impacts expressed by patients were the need to monitor/plan for urinary frequency, interference with/restriction of daily activities, and frustration or anxiety over diagnosis, symptoms, or treatment. Symptoms and impacts most frequently experienced by patients were typically not those with the greatest effects on their lives; rather, those with the greatest consequences were related to treatment.ConclusionsThe leading concerns associated with M0-CRPC were related to voiding and sexual dysfunction. The most relevant symptoms and impacts expressed by patients may be a consequence of therapy rather than of the disease.

[1]  Perspectives on treatment of metastatic castration-resistant prostate cancer. , 2013, The oncologist.

[2]  F. Saad,et al.  Current management of castrate-resistant prostate cancer. , 2010, Current oncology.

[3]  D. Wood,et al.  Stratification of postprostatectomy urinary function using expanded prostate cancer index composite. , 2013, Urology.

[4]  F. Saad,et al.  PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients. , 2014 .

[5]  J. Stanford,et al.  Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. , 2002, Journal of the National Cancer Institute.

[6]  O. Sartor,et al.  Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations. , 2015, Clinical genitourinary cancer.

[7]  B. Bokhour,et al.  Sexuality after treatment for early prostate cancer: exploring the meanings of "erectile dysfunction". , 2001, Journal of general internal medicine.

[8]  P. Scardino,et al.  A measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale development. , 2005, Clinical prostate cancer.

[9]  S. Fosså,et al.  An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. , 2008, European journal of cancer.

[10]  R. Greil,et al.  Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Sonn,et al.  Differing perceptions of quality of life in patients with prostate cancer and their doctors. , 2009, The Journal of urology.

[12]  N. Leidy,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  H. Payne,et al.  Symptoms and health-related quality of life in castration-resistant prostate cancer: the patient's perspective , 2012 .

[14]  B. Reeve,et al.  International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies , 2016, Quality of Life Research.

[15]  S. Daneshmand,et al.  Patient Related Outcome Measures Dovepress Androgen Deprivation Therapy for Prostate Cancer: Long-term Safety and Patient Outcomes , 2022 .

[16]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[17]  J. Cappelleri,et al.  Patient-reported outcomes: conceptual issues. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  E. Antonarakis,et al.  Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort , 2016, European urology.

[19]  B. Tombal,et al.  Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  D. Eton,et al.  Prostate cancer and health‐related quality of life: a review of the literature , 2002, Psycho-oncology.

[21]  I. Kim,et al.  Nonmetastatic Castration-Resistant Prostate Cancer , 2014, Korean journal of urology.

[22]  J. Beaumont,et al.  Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  Pennifer Erickson,et al.  Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  A. Katz What happened?: Sexual consequences of prostate cancer and its treatment , 2005 .

[25]  C. Morris,et al.  A STRUCTURED REVIEW OF PATIENT-REPORTED OUTCOME MEASURES (PROMs) FOR PROSTATE CANCER , 2009 .

[26]  Elizabeth Molsen,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  D. Lubeck,et al.  Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. , 1998, The Journal of urology.

[28]  David Cella,et al.  Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI) , 2003, Health and quality of life outcomes.

[29]  M. Fishman,et al.  Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer , 2007, Quality of Life Research.

[30]  John T. Wei,et al.  Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Hans T. Chung,et al.  Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[32]  Y. Loriot,et al.  ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer , 2015, Expert review of anticancer therapy.

[33]  S. Goldenberg,et al.  Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. , 2012, Current oncology.

[34]  R. A. Robinson,et al.  Patients' perceptions of quality of life after treatment for early prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  W. Linden,et al.  Measuring symptoms in localized prostate cancer: a systematic review of assessment instruments , 2013, Prostate Cancer and Prostatic Diseases.

[36]  John T. Wei,et al.  Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. , 2011, The Journal of urology.